<br>        General Inclusion Criteria:<br><br>          -  Patient must be female.<br><br>          -  Patient must be at least 18 years of age.<br><br>          -  Patient is able to verbally confirm understanding of risks, benefits and treatment<br>             alternatives and she or her legally authorized representative provides written<br>             informed consent prior to any study related procedure, as approved by the appropriate<br>             Medical Ethics Committee of the respective clinical site.<br><br>          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,<br>             silent ischemia, positive functional study or a reversible change in the<br>             electrocardiogram (ECG) consistent with ischemia).<br><br>          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)<br>             surgery.<br><br>          -  Patient must agree to undergo all protocol-required follow-up examinations.<br><br>          -  Patients of childbearing potential must have had a negative pregnancy test within 7<br>             days before treatment, and must not be nursing at the time of treatment.<br><br>        Angiographic Inclusion Criteria:<br><br>          -  Patients' artery morphology and disease is suitable to be optimally treated with a<br>             maximum of 4 planned study stents.<br><br>          -  Target lesions must be de novo lesions (no prior stent implant, no prior<br>             brachytherapy).<br><br>          -  Target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate.<br>             The diameter range will be expanded to 2.25 mm when the 2.25 mm stent is available.<br><br>          -  Target lesion greater than or equal to 28 mm in length by visual estimate.<br><br>        General Exclusion Criteria:<br><br>          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known<br>             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause<br>             non-compliance with the clinical investigation plan, confound the data interpretation<br>             or is associated with a limited life expectancy (i.e., less than one year).<br><br>          -  Patient has a known hypersensitivity or contraindication to aspirin, either heparin or<br>             bivalirudin, both clopidogrel and ticlopidine, everolimus, cobalt, chromium, nickel,<br>             tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be<br>             adequately pre-medicated.<br><br>          -  Participation in another device or drug study or has completed the follow-up phase of<br>             another study within the last 30 days.<br><br>          -  Patient who is judged to have a lesion that prevents complete inflation of an<br>             angioplasty balloon.<br><br>          -  Patient has had a previous stent implant, either Bare Metal Stent (BMS) or Drug<br>             Eluting Stent (DES) within the target vessel(s)<br>      ;<br>        General Inclusion Criteria:<br><br>          -  Patient must be female.<br><br>          -  Patient must be at least 18 years of age.<br><br>          -  Patient is able to verbally confirm understanding of risks, benefits and treatment<br>             alternatives and she or her legally authorized representative provides written<br>             informed consent prior to any study related procedure, as approved by the appropriate<br>             Medical Ethics Committee of the respective clinical site.<br><br>          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,<br>             silent ischemia, positive functional study or a reversible change in the<br>             electrocardiogram (ECG) consistent with ischemia).<br><br>          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)<br>             surgery.<br><br>          -  Patient must agree to undergo all protocol-required follow-up examinations.<br><br>          -  Patients of childbearing potential must have had a negative pregnancy test within 7<br>             days before treatment, and must not be nursing at the time of treatment.<br><br>        Angiographic Inclusion Criteria:<br><br>          -  Patients' artery morphology and disease is suitable to be optimally treated with a<br>             maximum of 4 planned study stents.<br><br>          -  Target lesions must be de novo lesions (no prior stent implant, no prior<br>             brachytherapy).<br><br>          -  Target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate.<br>             The diameter range will be expanded to 2.25 mm when the 2.25 mm stent is available.<br><br>          -  Target lesion greater than or equal to 28 mm in length by visual estimate.<br><br>        General Exclusion Criteria:<br><br>          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known<br>             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause<br>             non-compliance with the clinical investigation plan, confound the data interpretation<br>             or is associated with a limited life expectancy (i.e., less than one year).<br><br>          -  Patient has a known hypersensitivity or contraindication to aspirin, either heparin or<br>             bivalirudin, both clopidogrel and ticlopidine, everolimus, cobalt, chromium, nickel,<br>             tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be<br>             adequately pre-medicated.<br><br>          -  Participation in another device or drug study or has completed the follow-up phase of<br>             another study within the last 30 days.<br><br>          -  Patient who is judged to have a lesion that prevents complete inflation of an<br>             angioplasty balloon.<br><br>          -  Patient has had a previous stent implant, either Bare Metal Stent (BMS) or Drug<br>             Eluting Stent (DES) within the target vessel(s)<br>      ;<br>        General Inclusion Criteria:<br><br>          -  Patient must be female.<br><br>          -  Patient must be at least 18 years of age.<br><br>          -  Patient is able to verbally confirm understanding of risks, benefits and treatment<br>             alternatives and she or her legally authorized representative provides written<br>             informed consent prior to any study related procedure, as approved by the appropriate<br>             Medical Ethics Committee of the respective clinical site.<br><br>          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,<br>             silent ischemia, positive functional study or a reversible change in the<br>             electrocardiogram (ECG) consistent with ischemia).<br><br>          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)<br>             surgery.<br><br>          -  Patient must agree to undergo all protocol-required follow-up examinations.<br><br>          -  Patients of childbearing potential must have had a negative pregnancy test within 7<br>             days before treatment, and must not be nursing at the time of treatment.<br><br>        Angiographic Inclusion Criteria:<br><br>          -  Patients' artery morphology and disease is suitable to be optimally treated with a<br>             maximum of 4 planned study stents.<br><br>          -  Target lesions must be de novo lesions (no prior stent implant, no prior<br>             brachytherapy).<br><br>          -  Target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate.<br>             The diameter range will be expanded to 2.25 mm when the 2.25 mm stent is available.<br><br>          -  Target lesion greater than or equal to 28 mm in length by visual estimate.<br><br>        General Exclusion Criteria:<br><br>          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known<br>             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause<br>             non-compliance with the clinical investigation plan, confound the data interpretation<br>             or is associated with a limited life expectancy (i.e., less than one year).<br><br>          -  Patient has a known hypersensitivity or contraindication to aspirin, either heparin or<br>             bivalirudin, both clopidogrel and ticlopidine, everolimus, cobalt, chromium, nickel,<br>             tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be<br>             adequately pre-medicated.<br><br>          -  Participation in another device or drug study or has completed the follow-up phase of<br>             another study within the last 30 days.<br><br>          -  Patient who is judged to have a lesion that prevents complete inflation of an<br>             angioplasty balloon.<br><br>          -  Patient has had a previous stent implant, either Bare Metal Stent (BMS) or Drug<br>             Eluting Stent (DES) within the target vessel(s)<br>      ;<br>        General Inclusion Criteria:<br><br>          -  Patient must be female.<br><br>          -  Patient must be at least 18 years of age.<br><br>          -  Patient is able to verbally confirm understanding of risks, benefits and treatment<br>             alternatives and she or her legally authorized representative provides written<br>             informed consent prior to any study related procedure, as approved by the appropriate<br>             Medical Ethics Committee of the respective clinical site.<br><br>          -  Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina,<br>             silent ischemia, positive functional study or a reversible change in the<br>             electrocardiogram (ECG) consistent with ischemia).<br><br>          -  Patient must be an acceptable candidate for coronary artery bypass graft (CABG)<br>             surgery.<br><br>          -  Patient must agree to undergo all protocol-required follow-up examinations.<br><br>          -  Patients of childbearing potential must have had a negative pregnancy test within 7<br>             days before treatment, and must not be nursing at the time of treatment.<br><br>        Angiographic Inclusion Criteria:<br><br>          -  Patients' artery morphology and disease is suitable to be optimally treated with a<br>             maximum of 4 planned study stents.<br><br>          -  Target lesions must be de novo lesions (no prior stent implant, no prior<br>             brachytherapy).<br><br>          -  Target vessel reference diameter must be between 2.5 mm and 4.0 mm by visual estimate.<br>             The diameter range will be expanded to 2.25 mm when the 2.25 mm stent is available.<br><br>          -  Target lesion greater than or equal to 28 mm in length by visual estimate.<br><br>        General Exclusion Criteria:<br><br>          -  Patient has other medical illness (e.g., cancer or congestive heart failure) or known<br>             history of substance abuse (alcohol, cocaine, heroin etc.) that may cause<br>             non-compliance with the clinical investigation plan, confound the data interpretation<br>             or is associated with a limited life expectancy (i.e., less than one year).<br><br>          -  Patient has a known hypersensitivity or contraindication to aspirin, either heparin or<br>             bivalirudin, both clopidogrel and ticlopidine, everolimus, cobalt, chromium, nickel,<br>             tungsten, acrylic and fluoro polymers or contrast sensitivity that cannot be<br>             adequately pre-medicated.<br><br>          -  Participation in another device or drug study or has completed the follow-up phase of<br>             another study within the last 30 days.<br><br>          -  Patient who is judged to have a lesion that prevents complete inflation of an<br>             angioplasty balloon.<br><br>          -  Patient has had a previous stent implant, either Bare Metal Stent (BMS) or Drug<br>             Eluting Stent (DES) within the target vessel(s)<br>